Dr Vanathi Sivasubramaniam

Anatomical Pathology, Cytopathology & Histopathology Department

Dr Vanathi Sivasubramaniam

Dr Vanathi Sivasubramaniam MBBS, FRCPA completed her medical degree at the University of Queensland and obtained her Fellowship in Anatomical Pathology in 2011. Her specialist training was predominantly at St. Vincent’s Hospital (Sydney), with rotations at Liverpool Hospital, Prince of Wales Hospital and the Department of Forensic Medicine, Glebe. She concluded her training by completing the Geraldine Colby Zeiler Fellowship in Lung and Cytopathology at the Mayo Clinic, Arizona.

She was appointed as a Staff Specialist at St. Vincent’s in May 2011, where she continues as a Senior Staff Specialist. A Conjoint Senior Lecturer at the School of Clinical Medicine, UNSW Medicine & Health, Vanathi is passionate about the education of future medical practitioners and has been actively involved in undergraduate teaching and examinations since 2006.  She has been keenly engaged in the training of specialist registrars over many years, and recently took on the role of an examiner for the RCPA.

Vanathi is a member of the International Academy of Pathology, the Pulmonary Pathology Society, the Society for Cardiovascular Pathology, the International Society for Heart and Lung Transplantation, the International Association for the Study of Lung Cancer and the Australian Society of Cytology.

Vanathi’s areas of sub-specialty expertise include cardiovascular and pleuropulmonary pathology, covering both tumour and non-tumour related disease, with a deep focus on transplant related pathology, as well as mediastinal pathology, cytopathology, head and neck pathology, and medical renal pathology. As principle investigator for the Australasian arm of NCIC CTG BR.31: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of MEDI4736 in Completely Resected Non-Small Cell Lung Cancer, her extensive experience in PD-L1 immunohistochemistry led to her becoming an integral part of establishing protocols and reporting regimes for PD-L1 immunohistochemistry in lung carcinomas in Australia, with a lead role in the training of other pathologists, and in establishing a framework for ongoing quality assurance practices in conjunction with the RCPA.